Kenya Leads Groundbreaking HIV Prevention and Child Health Research

By: Cynthia Masibo

In a significant push towards enhancing public health, Kenyan scientists have unveiled groundbreaking research on HIV prevention and child health mortality at a high-profile symposium. Organized by the Kenya Medical Research Institute (KEMRI) in collaboration with international partners, the event spotlighted innovations that could redefine healthcare both locally and globally.

In her presentation, *New and Upcoming HIV Prevention Interventions*, Professor Nelly Mugo highlighted two landmark HIV prevention trials that are transforming the fight against the virus. The HIV Prevention Trials Network (HPTN) 083 and 084 studies have demonstrated that long-acting injectable cabotegravir (CAB LA), administered every eight weeks, reduces HIV incidence by 88% compared to the traditional daily oral regimen of tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), commonly known as Truvada.

“This advancement takes HIV prevention to a new level by providing an effective alternative for at-risk individuals who struggle with adherence to daily oral pills,” Prof. Mugo stated.

Another significant development is the use of subcutaneous Lenacapavir, administered every six months. Studies have shown that this treatment provides 100% protection against HIV among adolescent girls and young women and 98% among men who have sex with men. These findings underscore the potential for long-acting injectables to revolutionize HIV prevention and bring the world closer to the goal of HIV elimination.

Dr. Victor Akelo, a medical epidemiologist based at the Centre for Global Health Research at KEMRI, shared critical insights from the Child Health and Mortality Prevention Surveillance (CHAMPS) network. His presentation, *Use of Pathology-Based Surveillance to Improve Understanding of Causes of Under-Five Mortality*, emphasized the role of advanced surveillance methods in identifying underlying causes of child deaths.

Dr. Akelo, who serves as Senior Science Director at the CHAMPS network, highlighted how detailed postmortem analysis and pathology-based surveillance are enhancing the accuracy of child mortality data. “By using advanced diagnostics, we can better understand the specific causes of under-five mortality, allowing policymakers to implement more targeted interventions,” he explained.

The CHAMPS initiative, a collaboration between KEMRI, Emory University, the Liverpool School of Tropical Medicine (LSTM), and the US Centers for Disease Control and Prevention (CDC), is playing a pivotal role in shaping child health policies globally.

Dr. Serah Gitome, a Clinical Research Scientist and Acting Deputy Director of the Sexual Reproductive Adolescent and Child Health Programme at KEMRI, announced an upcoming symposium focused on sexual and reproductive health. The event, themed *Shaping the Next Decade in Sexual Reproductive Health: Bridging Knowledge, Technology & Care*, will bring together leading experts to discuss advancements in reproductive health and how to leverage technology to improve healthcare services.

“This symposium will serve as a platform to bridge the gap between research, innovation, and patient care, ensuring that scientific advancements translate into real-world impact,” Dr. Gitome stated.

As Kenya continues to champion medical research and innovation, these findings and initiatives provide hope for a future with better HIV prevention strategies, reduced child mortality, and improved reproductive health services.